<div id="readability-page-1">Mid-point pricing is the trend. AgomAb Therapeutics NV (AGMB), a Belgian biotech backed by Pfizer, priced its IPO at $16.00 – the mid-point of its range – last night. That put AgomAb Therapeutics right in step with SpyGlass Pharma (SPG) and Jennifer Garner’s Once Upon a Farm (OFRM) – both IPOs also priced at the mid-point of their respective ranges last night – after a brutal sell-off in the broad U.S. stock market. AgomAb Therapeutics NV (AGMB) priced 12.5 million American Depositary Shares (ADS) at $16.00 each to raise $200 million on Thursday night, Feb. 5, 2026. AgomAb’s ADS are expected to start trading today – Friday, Feb. 6, 2026 – on the NASDAQ. J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen were the joint book-runners. AgomAb Therapeutics NV (AGMB) is developing a pill to treat people with Crohn’s disease with fibrostenosis and an inhaled treatment for people with idiopathic pulmonary fibrosis (IPF). AgomAb will use the IPO’s proceeds to finance the Phase 2 clinical trials for its leading product candidates – ontunisertib (AGMB-129) – its pill for Crohn’s disease – about $120 million earmarked from the IPO – and AGMB-447 – its inhaled treatment for pulmonary fibrosis – about $80 million from the IPO, according to the prospectus. Pfizer owned a pre-IPO stake of 5.73 percent. Pfizer will hold a 4.1 percent stake after the IPO, the prospectus said. AgomAb Therapeutics, like most biotechs at the time they go public, is not profitable: AgomAb Therapeutics reported a net loss of $65.98 million on no product revenue for the 12 months that ended Sept. 30, 2025, according to financial statements in the prospectus. (For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.) Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board. To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message. Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.</div>

AgomAb Therapeutics NV (AGMB) has priced its IPO at $16.00, aligning with the mid-point trend, raising $200 million by offering 12.5 million American Depositary Shares. The funds will support Phase 2 trials for its Crohn’s disease pill and inhaled treatment for pulmonary fibrosis. Despite backing from Pfizer, AgomAb reported a net loss of $65.98 million with no product revenue for the past year. The shares are set to begin trading on NASDAQ.

- AgomAb Therapeutics NV (AGMB), a Belgian biotech backed by Pfizer, priced its IPO at $16.00, aligning with recent trends in the market.  
- The company raised $200 million by offering 12.5 million American Depositary Shares and plans to use the funds for Phase 2 clinical trials of its treatments for Crohn’s disease and idiopathic pulmonary fibrosis.  
- AgomAb reported a net loss of $65.98 million with no product revenue in the last year, with Pfizer's ownership decreasing from 5.73% to 4.1% post-IPO.

IPO Scoop

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Pfizer

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Direxion Daily Biotech Top 5 Bull 2X ETF

First Trust NYSE Arca Biotech Index Fd

The IPO Buzz: AgomAb Therapeutics (AGMB) Prices IPO at $16 & Joins ‘The Mid-Point Club’